Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Carcinoma, Spindle-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Carcinomatosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Mammary Carcinoma, Animal
|
0.300 |
Biomarker
|
disease |
CTD_human |
Global gene expression profiling of chemically induced rat mammary gland carcinomas and adenomas.
|
16316942 |
2005 |
Carcinoma
|
0.300 |
Biomarker
|
group |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Animal Mammary Neoplasms
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Mammary Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Anaplastic carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Carcinoma, Spindle-Cell
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Undifferentiated carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Carcinomatosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Mammary Carcinoma, Animal
|
0.300 |
Biomarker
|
disease |
CTD_human |
cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene.
|
12376462 |
2002 |
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In pancreatic cancer, LSR contributes to the epithelial barrier and malignancy via growth factors and may be a potential targeting molecule in the therapy.
|
31650247 |
2020 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Role of Tricellular Tight Junction Protein Lipolysis-Stimulated Lipoprotein Receptor (LSR) in Cancer Cells.
|
31330820 |
2019 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Lipolysis-stimulated lipoprotein receptor (LSR) is a lipoprotein receptor that binds to triglyceride-rich lipoproteins and related to some malignancies.
|
30250639 |
2018 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
LSR functions in the promotion of aggressive breast cancer phenotypes and poor patient outcome via differential subcellular localization to alter cell signaling, bioenergetics, and gene expression.Mol Cancer Res; 15(2); 165-78.©2016 AACR.
|
27856957 |
2017 |
Malignant Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
However, the detailed mechanisms of how the downregulation of LSR enhances cell invasion in cancer remain unclear.
|
29151917 |
2017 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
In endometriosis and endometrial cancer, LSR was observed not only in the subapical region but also throughout the lateral region as well as in normal endometrial epithelial cells in the secretory phase, and LSR in the cancer was reduced in correlation with the malignancy.
|
27036040 |
2016 |
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Herein, we sought to define the role of lipolysis stimulated lipoprotein receptor (LSR) in breast cancer and cancer cell behavior as LSR was recently correlated with tumor-initiating features.
|
24637461 |
2014 |